摘要
目的比较不同剂量表柔比星膀胱灌注预防浅表性膀胱癌术后复发的疗效和安全性。方法90例浅表性膀胱癌患者根据开放的、前瞻性的、随机分组的方法,分别采用不同剂量表柔比星膀胱内灌注化疗,随访2年,观察患者肿瘤复发和不良反应。结果表柔比星80mg单次灌注组、40mg多次灌注组和50mg多次灌注组术后1年复发率分别为16.7%、13.3%和16.7%,2年复发率分别为50.0%、36.7%和36.7%。3组术后1年复发率差异无统计学意义(P>0.05),但2年时单次灌注组的复发率显著高于多次灌注组(P<0.05)。表柔比星80mg单次灌注组、40mg多次灌注组和50mg多次灌注组的不良反应发生率分别为23.3%、40.0%和33.3%,灌注次数愈多,不良反应发生率愈高。结论表柔比星术后早期、单次、大剂量灌注配合每月1次低剂量灌注预防浅表性膀胱癌复发,可能是一种安全、经济、有效的方法。
Objective To investigate the efficiency and safety of different regimens by intravesical instillation of epirubicin, a derivative of adriamycin, for the prevention of primary superficial bladder carcinoma from recurrence. Methods Ninety patients supplemented with intravesical epirubicin instillation after operation were randomly divided into three groups： Group A- 80 mg in one dose; Group B- repeated epirubicin 40 mg q wk x 4-8 sessions followed by q month to the end of the second year; or Group C -50 mg q month to the same duration. All patients were followed up for two years by observing the recurrence rates and side effects. Results The recurrence rate of groups A, B and C at one year was 16.7 %, 13.3 % and 16.7 %, respectively, without any significant difference observed. However, it was 50.0%, 36.7% and 36.7% at two years, at which time the recurrence rate of group A was significantly higher than those of groups B and C. The side effects rate was 23.3 %, 40.0% and 33.3% for groups A, B and C, repectively. The more instillations the patients had, the more severe side effects were. Conclusion Early postoperative single high dose intravesical instillation of epirubicin combined with repeated lower doses of the same drug every month may be an efficient and safe regimen to prevent the primary superficial bladder carcinoma from recurrence.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2005年第8期507-509,共3页
Chinese Journal of Oncology
